ABL Bio Inc
KOSDAQ:298380
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Jubilant Ingrevia Ltd
NSE:JUBLINGREA
|
IN |
|
Shanghai Nenghui Technology Co Ltd
SZSE:301046
|
CN |
|
Tongling Nonferrous Metals Group Co Ltd
SZSE:000630
|
CN |
ABL Bio Inc
Accrued Liabilities
ABL Bio Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Accrued Liabilities
₩462.2m
|
CAGR 3-Years
36%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Accrued Liabilities
₩191.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
16%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Accrued Liabilities
₩52.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Accrued Liabilities
₩449.2m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Accrued Liabilities
₩375m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
18%
|
|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
Accrued Liabilities
₩4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ABL Bio Inc
Glance View
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
See Also
What is ABL Bio Inc's Accrued Liabilities?
Accrued Liabilities
462.2m
KRW
Based on the financial report for Dec 31, 2025, ABL Bio Inc's Accrued Liabilities amounts to 462.2m KRW.
What is ABL Bio Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
36%
Over the last year, the Accrued Liabilities growth was 16%. The average annual Accrued Liabilities growth rates for ABL Bio Inc have been 36% over the past three years , 36% over the past five years .
